For this reason, there is a need to find novel indicators that more accurately reflect the disease burden and the response to treatment, and correlate to patients’ outcomes in myeloma with the IgA isotype (about 30–40% of patients) [39]. The gene discussed is CD79A; the disease is plasma cell myeloma.